Imperfect memory and the development of Haemophilus influenzae type b disease

Pediatric Infectious Disease Journal

Volumn 20, Issue 3, 2001, Pages 235-239

  Lucas, Alexander H ^a   Granoff, Dan M ^a  

^a CHILDREN S HOSPITAL OAKLAND RESEARCH INSTITUTE   (United States)

Author keywords

Haemophilus disease; Immunologic memory

Indexed keywords

BACTERIUM ANTIBODY;

AGING; HAEMOPHILUS INFLUENZAE TYPE B; HUMAN; IMMUNE RESPONSE; IMMUNITY; IMMUNOLOGICAL MEMORY; INFLUENZA; MEMORY; MEMORY CELL; PRIORITY JOURNAL; REVIEW; VACCINATION;

ANTIBODIES, BACTERIAL; HAEMOPHILUS INFECTIONS; HAEMOPHILUS INFLUENZAE TYPE B; HAEMOPHILUS VACCINES; HUMANS; IMMUNOLOGIC MEMORY; POLYSACCHARIDES, BACTERIAL;

EID: 0035078238     PISSN: 08913668     EISSN: None     Source Type: Journal    
DOI: 10.1097/00006454-200103000-00002     Document Type: Review

References (51)

1. Human serum activities against Hemophilus influenzae, type b
2. Immunity to disease caused by Hemophilus influenzae, type b: II. Specificity and biologic characteristics of "natural," infection-acquired, and immunization-induced antibodies to the capsular polysaccharide of Hemophilus influenzae, type b
3. An Escherichia coli antigen cross-reactive with the capsular polysaccharide of Haemophilus influenzae type b: Occurrence among known serotypes, and immunochemical and biologic properties of E. coli antisera toward H. influenzae type b
4. Induction of serum Haemophilus influenzae type B capsular antibodies in adult volunteers fed cross-reacting Escherichia coli 075:K100:H5
5. Cross-reactive antigens and immunity to diseases caused by encapsulated bacteria
6. The protective level of serum antibodies to the capsular polysaccharide of Haemophilus influenzae type b
7. The protective level of serum antibodies to the capsular polysaccharide of Haemophilus influenzae type b
8. Difficulties in establishing a serological correlate of protection after immunization with Haemophilus influenzae conjugate vaccines
9. Immunogenicity assays and surrogate markers to predict vaccine efficacy
10. Laboratory correlates of protection against Haemophilus influenzae type b disease: Importance of assessment of antibody avidity and immunologic memory
11. Functional affinity of antibody to the Haemophilus influenzae type b polysaccharide
12. Variability in the functional activity of vaccine-induced antibody to Haemophilus influenzae type b
13. Avidity and bactericidal activity of antibody elicited by different Haemophilus influenzae type b conjugate vaccines
14. Oligosaccharide-protein conjugate vaccines induce and prime for oligoclonal IgG antibody responses to the Haemophilus influenzae b capsular polysaccharide in human infants
15. Immunologic priming to capsular polysaccharide in infants immunized with Haemophilus influenzae type b polysaccharide-Neisseria meningitidis outer membrane protein conjugate vaccine
16. Antibody avidity as a surrogate marker of successful priming by Haemophilus influenzae type b conjugate vaccines following infant immunization
17. Combined vaccination of Haemophilus influenzae type b conjugate and diphtheria-tetanus-pertussis containing acellular pertussis
18. Serum antibodies after vaccination with Haemophilus influenzae type b capsular polysaccharide and responses to reimmunization: No evidence of immunologic tolerance or memory
19. Immunological response to conjugate vaccines in infants: Follow up study
20. The induction of immunologic memory after vaccination with Haemophilus influenzae type b conjugate and acellular pertussis-containing diphtheria, tetanus, and pertussis vaccine combination
21. Evidence for induction of polysaccharide specific B-cell-memory in the 1st year of life: Plain Haemophilus influenzae type b-PRP (Hib) boosters children primed with a tetanus-conjugate Hib-DTPa-HBV combined vaccine
22. Administration of combined diphtheria and tetanus toxoids and pertussis vaccine, hepatitis B vaccine, and Haemophilus influenzae type b vaccine to infants and response to a booster dose of Hib conjugate vaccine
23. A high degree of natural immunologic priming to the capsular polysaccharide may not prevent Haemophilus influenzae type b meningitis
24. Circulating polyribophosphate in Hemophilus influenzae, type b meningitis: Correlation with clinical course and antibody response
25. Serologic responses of children with meningitis due to Haemophilus influenzae type b
26. Countercurrent immunoelectrophoresis in the diagnosis of Haemophilus influenzae type b infection: Relationship of detection of capsular antigen to age, antibody response, and therapy
27. Prospective surveillance of Haemophilus influenzae type b disease in Dallas County, Texas, and in Minnesota
28. The 1996 Albert Lasker Medical Research Awards: Prevention of systemic infections, especially meningitis, caused by Haemophilus influenzae type b: Impact on public health and implications for other polysaccharide-based vaccines
29. Quantitative measurement of "natural" and immunization-induced Haemophilus influenzae type b capsular polysaccharide antibodies
30. Protection from infection with Haemophilus influenzae type b by monoclonal antibody to the capsule
31. Functional differences in idiotypically defined IgG1 anti- polysaccharide antibodies elicited by vaccination with Haemophilus influenzae type b polysaccharide-protein conjugates
32. Prevention of Haemophilus influenzae type b infections in Apache and Navajo children
33. The progeny of a single virgin B cell predominates the human recall B cell response to the capsular polysaccharide of Haemophilus influenzae type b
34. The first dose of a Haemophilus influenzae type b conjugate vaccine reactivates memory B cells: Evidence for extensive clonal selection, intraclonal affinity maturation, and multiple isotype switches to IgA2
35. Immunogenetic analysis of the immune response to pneumococcal polysaccharide
36. Combinatorial library cloning of human antibodies to Streptococcus pneumoniae capsular polysaccharides: Variable region primary structures and evidence for somatic mutation of Fab fragments specific for capsular serotypes 6B, 14 and 23F
37. Induction of immunologic memory in infants primed with Haemophilus influenzae type b conjugate vaccines
38. A randomized, prospective field trial of a conjugate vaccine in the protection of infants and young children against invasive Haemophilus influenzae type b disease
39. Finnish efficacy trials with Haemophilus influenzae type b vaccines
40. Rapid disappearance of Haemophilus influenzae type b meningitis after routine childhood immunisation with conjugate vaccines
41. High antibody responses to booster doses of either Haemophilus influenzae capsular polysaccharide or conjugate vaccine after primary immunization with conjugate vaccines
42. Vaccine failures after primary immunisation with Haemophilus influenzae type-b conjugate vaccine without booster
43. Prospects for prevention of Haemophilus influenzae type b disease by immunization
44. Prevention of Hemophilus influenzae type b bacteremic infections with the capsular polysaccharide vaccine
45. Host and bacterial factors associated with Haemophilus influenzae type b disease in Minnesota children vaccinated with type b polysaccharide vaccine
46. Hemophilus influenzae type B disease in children vaccinated with type B polysaccharide vaccine
47. Lack of efficacy of Haemophilus b polysaccharide vaccine in Minnesota
48. Vaccines for Haemophilus influenzae type b
49. Declining incidence of Haemophilus influenzae type b disease since introduction of vaccination
50. Decline of childhood Haemophilus influenzae type b (Hib) disease in the Hib vaccine era